Nuohui Health is expected to increase gross profit in the first half of the year, which is only over 637.7% of the launch of only half a year.

On July 15th, Nuohui Health (HK06606, the stock price of HK $ 24.25, and a market value of HK $ 10.421 billion) issued a profit trailer stating that as of June 30, 2022, according to the unveiled operating data, the Group's revenue and gross profit margin increased in the first half of the year, the growth of growth and gross profit margin increased Strong.

Specifically, the total revenue of the Group's first half of 2022 is expected to be 217.1 million yuan to 231.6 billion yuan, an increase of 394.5%to 427.6%year -on -year; gross profit is expected to be 182.2 million to 191 million yuan, a year -on -year increase of 637.7%to 673.7%.

For the increase in income and gross profit, the company attributed to the product, that is, the income and gross profit of the early screening product "Chang Weiqing", the stool hidden blood test agent "tube", and the pylori that was listed in January Detecting the product "quiet tube".

Among the three products, the shortest sales revenue in the first half of this year is expected to have the highest sales revenue in the first half of this year, with 81 million to 84.5 million yuan, and the gross profit for sales is 73.7 million yuan to 75.5 million yuan.

The sales revenue in the first half of Chang Weiqing was expected to be 69.4 million to 76.9 million yuan, a year -on -year increase of 388.7%to 441.5%; the gross profit for sales of sales was 55.4 million to 60.4 million yuan, an increase of 592.5%to 655.0%year -on -year.

In the first half of the year, the sales revenue was expected to be 66.6 million to 70.1 million yuan, a year -on -year increase of 125.0%to 136.8%; the gross profit for sales of sales was 53.7 million to 55.5 million yuan, an increase of 208.6%to 219.0%year -on -year.

Regarding the income and profit of Chang Weiqing and the tube, Nuohui Health is attributed to its increase in sales and confirmation of income.

However, the increasing income from Chang Weiying also stems from the increase in channels with higher single test income (such as hospitals and direct facing consumer channels). The rise in units' product revenue is also one of the reasons for the increase in sales revenue and gross profit in pipelines.

In terms of profitability, the gross profit margin of Nuohui is expected to be 78.7%to 88.0%in the first half of the year, which is on the rise from 56.2%in the same period last year.

Among them, Chang Weiqing's gross profit margin in the first half of this year is expected to be 72.0%~ 87.0%, and the level in the first half of last year is about 56.6%; %; The gross profit margin of the Youyou Pipe in the first half of the year is expected to be 87.2%to 93.2%.

The announcement shows that Chang Weiqing's gross profit margin has benefited from the scale economy, and the cost of single testing has decreased; the increase in single test income directly -facing consumer channels; and a more favorable channel combination, which makes it from a single test income from a single test income. The proportion of higher hospitals and direct revenue for consumer channels has increased.

The reason for the increase in gross profit margin in the pipe is increased by the increase in single test income (including all channels and single channels) and the production cost of unit production.

Daily Economic News

- END -